Osteoporosis International

, Volume 21, Supplement 2, pp 431–436

Strontium ranelate: an effective solution for diverse fracture risks


DOI: 10.1007/s00198-010-1241-2

Cite this article as:
Ringe, J.D. Osteoporos Int (2010) 21(Suppl 2): 431. doi:10.1007/s00198-010-1241-2


Osteoporosis is listed by the WHO among the ten most frequent and socio-economically important, chronic diseases of mankind. The term osteoporosis however comprises a number of different pathophysiological conditions and clinical situations of weakened bones with increased risk of fragility fractures. A modern anti-osteoporotic drug should provide qualified study results proving therapeutic efficacy over this broad range of daily clinical appearances of osteoporosis. The decision for treatment in the individual patients depends no longer only on bone mineral density. Today, the major criterion for decision making is the prospective 10-year risk for fractures. Since this risk is calculated on the basis of age, sex, bone mineral density, prevalent fractures, and a number of other contributing risk factors (Kanis et al., Osteoporos Int 12:989–995, 2001; Kanis et al., Osteoporos Int 19:385–397, 2008), it seems to be of interest to have a look whether the fracture-reducing potency of a drug is influenced by these risk factors. The purpose of this review is to analyze whether the fracture-reducing efficacy of strontium ranelate in patients with osteoporosis can be achieved independently of sex, etiology of osteoporosis, and the major diagnostically relevant risk factors.


Body mass indexGenderGlucocorticoidsHeredityOsteoporosisSmokingStrontium ranelate

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010

Authors and Affiliations

  1. 1.General Internal Medicine and West-German Osteoporosis Center (WOC)Klinikum LeverkusenLeverkusenGermany